Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 30 October 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Revenue fell below the forecast due to a decline in the number of cases secured in the fourth quarter as a result of a series of reported incidents in Japan, as well as a decline in the number of cases involving artificial knee joints in the United States. In addition to the decrease in gross profit resulting from lower revenue, manufacturing overhead costs, including labor costs incurred in responding to product supply requirements, increased, causing manufacturing costs to exceed assumptions. In addition, income taxes—adjustments increased after the recoverability of deferred tax assets was reassessed using more conservative assumptions and a portion of the assets was written down.
| Item | Details |
|---|---|
| Net Sales | ¥24,800 million → ¥23,917 million（-3.6%） |
| Operating profit | ¥700 million → ¥574 million（-18.0%） |
| Ordinary income | ¥550 million → ¥534 million（-2.9%） |
| Profit attributable to owners of the parent | ¥300 million → ¥263 million（-12.3%） |
| Net income per share | ¥11.38 → ¥9.99 |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 30 October 2025 |
| Previous-period results | Net Sales ¥25,114 million (¥ for net income per share) / Operating profit ¥1,555 million (¥ for net income per share) / Ordinary income ¥1,488 million (¥ for net income per share) / Profit attributable to owners of the parent ¥-461 million (¥ for net income per share) / Net income per share ¥-17.54 million (¥ for net income per share) |
| Reason for the revision | Revenue fell below the forecast due to a decline in the number of cases secured in the fourth quarter as a result of a series of reported incidents in Japan, as well as a decline in the number of cases involving artificial knee joints in the United States. In addition to the decrease in gross profit resulting from lower revenue, manufacturing overhead costs, including labor costs incurred in responding to product supply requirements, increased, causing manufacturing costs to exceed assumptions. In addition, income taxes—adjustments increased after the recoverability of deferred tax assets was reassessed using more conservative assumptions and a portion of the assets was written down. |
| Dividend forecast revision | Annual dividend maintained at ¥17 per share, as forecast in the previous announcement (no change) |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In Japan, the number of cases secured in the fourth quarter declined due to the impact of a series of reported incidents, while in the United States the number of cases involving artificial knee joints also declined, causing revenue to fall below the forecast. Operating profit fell short of the forecast because, in addition to the decrease in gross profit resulting from lower revenue, manufacturing overhead costs, including labor costs incurred in responding to product supply requirements, increased. In addition to these factors, net income fell short of the forecast because income taxes—adjustments increased after the recoverability of deferred tax assets was reassessed using more conservative assumptions and a portion of the assets was written down.